PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026Journal of Gastroenterology2 citationsOpen Access

Covert hepatic encephalopathy as a multi-organ syndrome: the gut–liver–muscle–brain axis, diagnosis, treatment, and multidisciplinary care

TMTakao MiwaCHCynthia L. HsuMSMasahito Shimizu

Key Points

  • This review aims to elucidate the pathophysiology, diagnosis, and therapeutic management of covert hepatic encephalopathy (CHE).
  • Summarized evidence on CHE pathophysiology, focusing on gut–liver–muscle–brain interactions.
  • Discussed diagnostic testing including psychometric batteries and point-of-care tools like the Stroop test.
  • Reviewed therapeutic options ranging from traditional treatments to microbiome-targeted therapies.
  • CHE significantly impacts quality of life and is linked to increased mortality.
  • Inadequate implementation of screening and treatment protocols leaves many patients undiagnosed.
  • Emphasized the role of multidisciplinary teams in improving outcomes for patients with CHE.

Abstract

Covert hepatic encephalopathy (CHE) is a highly prevalent complication of liver cirrhosis. Despite the absence of overt symptoms, CHE is strongly associated with impaired quality-of-life, overt hepatic encephalopathy, and mortality. Over the past two decades, evidence regarding the pathophysiology, diagnosis, and treatment of CHE has accumulated considerably, and clinical guidelines recommend screening in patients with cirrhosis. Nevertheless, diagnostic and therapeutic algorithms have not been fully implemented in real-world practice, and many patients remain undiagnosed and untreated. Understanding the natural history of CHE is essential to improve cirrhosis care, as it provides a framework for appropriate screening, treatment decision-making, and patient counseling. CHE is a multi-organ syndrome with complex interactions between the liver, gut, skeletal muscle, kidneys, and brain, with impaired ammonia handling and systemic inflammation acting as central drivers of this organ crosstalk. Hyperammonemia induces astrocytic dysfunction, brain edema, and neuroinflammation, while systemic inflammation, oxidative stress, sarcopenia, gut dysbiosis, and altered microbial metabolites, including bile acids and short-chain fatty acids, further modulate disease expression. In this review, we summarize current understanding of CHE pathophysiology, diagnostic testing, including psychometric batteries and point-of-care tools, such as the Stroop test and animal naming test, and therapeutic options, ranging from lactulose and rifaximin to microbiome-targeted approaches, including fecal microbiota transplantation. We also highlight major challenges in CHE management, including limited implementation of testing, inadequate biomarkers, diagnostic difficulties in geriatric cirrhosis, and unmet needs in fall and driving risk management, and emphasize the importance of multidisciplinary team-based approaches to improve patient outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Miwa et al. (2026) studied this question.

synapsesocial.com/papers/6a002147c8f74e3340f9c2c3https://doi.org/10.1007/s00535-026-02425-1
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Covert hepatic encephalopathy: a neglected topic—a narrative review2024 · 2 citations
  2. 2Chinese Consensus on Clinical Diagnosis and Management of Covert Hepatic Encephalopathy2025 · 1 citations
  3. 3Other causes of neurocognitive impairment than covert hepatic encephalopathy (<scp>CHE</scp>) are very frequent, either alone or associated with <scp>CHE</scp>, in cirrhotic patients with cognitive complaints2024 · 4 citations
  4. 4An Association of Covert Hepatic Encephalopathy with Non-elderly and MASLD in Patients with Chronic Liver Disease: Data-mining Analyses2026
  5. 5Evaluation of Quality of Life and Risk Factors in Patients With Covert Hepatic Encephalopathy Including Those With Hepatocellular Carcinoma.2026